Y. Suzuki et al., EFFECTS OF CP-060S, A NOVEL CARDIOPROTECTIVE DRUG, ON CARDIAC-FUNCTION AND MYOCARDIAL OXYGEN-CONSUMPTION, General pharmacology, 32(1), 1999, pp. 57-63
1. We examined the effects of CP-060S on cardiac function and myocardi
al oxygen consumption (MVO2) in anesthetized dogs. 2. CP-060S (10-300
mu g/kg IV) decreased heart rate, increased aortic flow and decreased
mean blood pressure in a dose dependent manner, The PR interval was si
gnificantly prolonged by administration of CP-060S (300 mu g/kg IV): 3
. CP-060S (10-300 mu g/kg IV) increased coronary blood flow in a dose
dependent manner. Left ventricular end-diastolic pressure and maximal
first derivative of left ventricular pressure were not significantly a
ffected. 4. CP-060S (10-300 mu g/kg IV) increased coronary sinus blood
flow and decreased arteriovenous oxygen difference and MVO2 in a dose
dependent manner. 5. The effects of CP-060S on cardiac function and M
VO2 are qualitatively similar to those of diltiazem, a typical Ca2+ an
tagonist, (C) 1998 Elsevier Science Inc.